Eli Lilly has spent the final decade remodeling from a dependable however unremarkable dividend payer into one of the vital talked-about shares on Wall Road.
Its weight problems and diabetes franchise, constructed round tirzepatide, the lively ingredient in each Zepbound and Mounjaro, has despatched the dividend inventory hovering and reshaped how buyers take into consideration the pharmaceutical sector.
Valued at a market cap of $883 billion, Eli Lilly (LLY) inventory has returned greater than 1,500% up to now decade, after adjusting for dividend reinvestments. Regardless of these outsized features, it’s down 13% from all-time highs.
Lilly introduced in $65.2 billion in income final yr, a jaw-dropping 45% progress price for an organization that is been round since 1876.
However HSBC simply dropped a blunt verdict on the inventory, and it is one which revenue buyers ought to take significantly.
HSBC turns bearish on Eli Lilly inventory
HSBC downgraded LLY inventory to “reduce” from “hold” and reduce its value goal to $850 from $1,070. With the inventory at the moment buying and selling close to $989, that focus on implies significant draw back from right this moment’s degree.
The agency’s concern is not that Lilly is a nasty firm. It is that expectations have run too sizzling.
Associated: Eli Lilly’s capsule solves the most important downside with weight reduction
Wall Road broadly assumes the weight problems drug market will ultimately surpass $150 billion. HSBC’s personal estimate places the complete addressable market someplace between $80 billion and $120 billion by 2032, a large hole that might depart buyers upset.
The financial institution additionally pointed to pricing stress as a severe problem. Worth cuts in 2026 signify a transparent headwind for Lilly, and HSBC urged that a lot of the current gross sales momentum is being pushed extra by pricing dynamics than true product differentiation.
LLY inventory dividend snapshot
Eli Lilly has paid a dividend for nearly 30 years and has raised the payout for 12 consecutive years, in response to Fiscal.ai knowledge. Since 2014, Eli Lilly has elevated its dividend at an annual price of 11%.
Analysts forecast the well being care heavyweight to extend free money move from $9 billion in 2025 to over $47 billion in 2030.
Extra Dividend Shares:
- Dividend-paying restaurant inventory stumbles as gasoline costs surge
- Megacap dividend inventory might make sweeping layoffs to offset AI prices
- 156-year-old power big to pay $17 billion in dividends as oil spikes to $110
Given an annual dividend expense of $6.2 billion, Eli Lilly has sufficient room to boost dividends at an accelerated tempo.
Wall Road estimates the dividend payout to virtually double by way of 2030.
However its yield is modest given how a lot the inventory has appreciated. This is what buyers ought to know.
- Annual dividend: Roughly $6.92 per share
- Dividend yield: Roughly 0.70% (primarily based on a share value of about $989)
- 12-year dividend progress price: Roughly 11% yearly
- Consecutive years of dividend payout: 29 years
- Ex-dividend frequency: Quarterly
The low yield will not appeal to income-focused buyers on the lookout for fast money move. However the low payout ratio and double-digit dividend progress price sign that Lilly has the capability to maintain elevating its dividend nicely into the long run, even because it continues to take a position aggressively in its pipeline.
Orforglipron launch might disappoint
One of many greatest wild playing cards heading into the second half of 2026 is the launch of orforglipron: Lilly’s oral weight problems capsule, awaiting Meals and Drug Administration approval, anticipated as early as April.
HSBC flagged that compliance and persistence charges for oral medicine might underperform expectations, and that discontinuation charges seen in scientific trials recommend the market is getting forward of actuality.
Eli Lilly has a widening product portfolio.
Porrini/Shutterstock
Eli Lilly CFO Lucas Montarce pushed again on that skepticism in the course of the Cowen convention, saying Lilly feels “really good” in regards to the product profile and highlighted a key comfort benefit.
Not like Novo Nordisk’s Wegovy capsule, which requires sufferers to take it with restricted water and wait half-hour earlier than consuming, orforglipron has no such meals or water restrictions.
Montarce additionally famous the drug is a day by day remedy the place ease of use will matter over time.
Nonetheless, Novo Nordisk’s oral Wegovy reached 50,000 weekly prescriptions in underneath three weeks, CNBC reported. Lilly will likely be getting into a market the place the competitors already has a head begin and model recognition working in its favor.
Associated: The Dow’s finest dividend shares: A shortlist for revenue buyers
What LLY inventory buyers ought to watch
HSBC’s downgrade is not a demise sentence for LLY. Wall Road value targets for the inventory vary from $850 to $2,000, which tells you simply how huge the disagreement is correct now.
The near-term story hinges on orforglipron’s approval and early launch efficiency. If the capsule features traction with sufferers who’ve been ready for a handy oral choice, the bears may look silly rapidly.
If compliance charges disappoint or pricing stress bites more durable than anticipated, HSBC’s $850 goal begins to look much more cheap.
For long-term dividend buyers, the larger image is that this:
- Lilly has almost quadrupled in measurement over the past decade.
- Its pipeline extends nicely past weight problems into heart problems, oncology, Alzheimer’s illness, and immunology.
- And with Medicare protection for anti-obesity medicines set to start no later than July 1, quantity may develop in ways in which assist offset the pricing headwinds.
HSBC could also be proper that the inventory is priced for perfection. However the firm itself is way from a damaged story.
Associated: Barclays names 2 drug shares buyers ought to personal in 2026
